A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...